Brind.
  1. Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

Amgen and Novartis have developed similar drugs aimed at treating heart conditions.

6 reports, 1 independent Updated Sep 17
Gone quiet Reached 2 outlets in its first 24 hours
Reports
6
Developments
3
Repetition
83%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amgen and Novartis have developed similar drugs aimed at treating heart conditions.

Who's involved

What this event is mainly about
AmgenNovartis

How it developed

Newest first. Tap a step to see who reported it.
  1. A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.Sub-event
  2. Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.Sub-event
  3. Amgen and Novartis are developing similar drugs for heart disease.1 source

Keep exploring

Part of

Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

Also in this story

All 7 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
5 more outlets ran the same wire story